Edaglitazone is an agonist of peroxisome proliferator-activated receptor γ (PPARγ). It activates PPARγ in a reporter assay using CV-1 cells expressing murine PPARγ2 when used at concentrations ranging from 0.1 to 1 μM. Edaglitazone (1, 5, and 25 μM) increases [3H]2-deoxyglucose transport in the presence and absence of insulin and increases glycogen synthesis in the presence of insulin in soleus muscle strips isolated from obese rats.
Edaglitazone possesses anti-diabetic properties and is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPARγ) agonist. Also, it is a cytochrome P 450 2C19 (CYP2C19) substrate.
Treatment of Type 2 diabetes.